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Abstract— With the current scientific knowledge, there is no 
medical device which can handle continuous infusion cancer 
therapy. Hence, only a quasi continuous infusion therapy can 
be achieved using discrete drug administration (which can be 
sufficiently frequent). Therefore, a discrete time control has 
to be designed for a tumor growth model for real-life 
application. We designed state feedback control, augmented 
with setpoint control to follow nonzero reference signal, and 
also augmented with actual state observer due to the fact that 
we are unable to measure all states of the system. In addition, 
the control system contains load estimation as well to 
investigate the effect of disturbance on the input of the 
model. 
 
I. INTRODUCTION 
Nowadays in cancer treatment there is a wide scale of 
available therapies. A recent treatment type is called as 
Targeted Molecular Therapies (TMTs) which aim to fight 
directly against specific, identified cancer mechanisms. A 
promising target method is to inhibit tumor 
vascularization because if we can cease the process of 
angiogenesis (new blood vessel formation), tumor growth 
is limited. This leads to a new approach where the point is 
not to eliminate the whole cancer but to keep it in a 
controlled steady state. 
We investigated a well-known tumor growth model 
under antiangiogenic therapy [1] and designed several 
continuous time controllers like LQ control method and 
state observer [2-4], flat control [5-7], modern robust 
control method [8-10], feedback linearization method 
[11], and adaptive fuzzy techniques [12]. However, with 
the current scientific knowledge, there is no medical 
device which can handle continuous infusion cancer 
therapy [13]; hence we oriented in the current research 
work on discrete time control. 
The paper is organized as follows. In Section II, we 
present the nonlinear model of tumor growth under 
angiogenic inhibition, and describe a linear model which 
is acquired by working point linearization. Section III 
contains the description of the design structure including 
state feedback, setpoint control, actual state observer and 
load estimation. In Section IV, we present the simulation 
results. The paper ends with the conclusion in Section V. 
II. THE APPLIED MODEL OF TUMOR GROWTH  
P. Hahnfeldt et al. created a dynamic model for tumor 
growth under antiangiogenic therapy [1]. In their 
experiment mice were injected with Lewis lung carcinoma 
cells and they have investigated the effect of three 
different angiogenic inhibitors (angiostatin, endostatin and 
TNP-470). The original model was analyzed and modified 
in several studies [14-16]. The most important alteration is 
the continuous infusion therapy [15], where the input (the 
inhibitor administration rate) is equal to the concentration 
of administered inhibitor (serum level of inhibitor). 
The model which takes into account the continuous 
infusion therapy is the following second-order system: 
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where x1 is the tumor volume (mm3), x2 is the endothelial/ 
vascular volume (mm3) and g is the concentration of the 
administered inhibitor (mg/kg). The model contains the 
following parameters: λ1 is the tumor growth rate (1/day), 
b is the stimulatory capacity of the tumor to the 
vasculature (1/day), d is the endogenous inhibition of 
previously generated vasculature (1/(day·mm2)), e is the 
antiangiogenic effect of the administered inhibitor on the 
tumor vasculature (kg/(day·mg)). 
Parameter values for the considered Lewis lung 
carcinoma and the mice used in the experiment are [1]:  
λ1 = 0.192 1/day, b = 5.85 1/day, d = 0.00873 1/day·mm2. 
The experiment has shown that the most effective 
inhibitor was endostatin; therefore, we have applied this 
antiangiogenic drug in controller design (eendostatin = 0.66 
kg/(day·mg)).  
From equation (1) it is clear that the system is in steady-
state when tumor and vascular volumes are equal. Tumor 
growth without antiangiogenic therapy leads to high 
steady-state tumor volume (1.734ˇ104 mm3) and it 
represents the lethal steady-state case.  
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Since state feedback control design requires linear 
model, we have applied operating point linearization in 
the g0 = 0 working point. The matrices of the linear 
model are: 
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III. CONTROLLER DESIGN 
In the case of discrete time controller design, the closed 
loop contains a DAC (digital to analog converter) right 
before the tumor model in the feedforward branch, which 
is modeled by a zero-order hold. In the feedback branch, 
right after the model, an ADC (analog to digital converter) 
can be found (Fig.1). The whole controller structure was 
designed for the linearized and discretized tumor growth 
model; however, the simulations were carried out with the 
original nonlinear continuous model. Controller design 
was executed in Matlab 7.9.0 (R2009b). 
A. Sampling time, observability and controllability of 
the linearized discrete model 
Sampling time (Td) was chosen to fulfill the conditions 
of Shannon theorem for every signal of the accelerated 
system.  
Taking into account a discrete time model which can be 
represented by the following state space and output 
equations: 
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the controllability and observability matrices are as 
follows: 
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where n is the dimension of the state variables. To fulfill 
the conditions of controllability and observability, MC and 
MO have to be full rank (rank MC = n = dim x, rank MO = n 
= dim x). The matrices are full rank for every  
nonzero operating point; thus, the system is controllable 
and observable. 
B. State feedback  
The general state feedback law is given by : 
,ii Kxu −= (12) 
where K can be calculated based on pole placement or LQ 
control method. The state equation of the closed loop 
system using state feedback is: 
( ) .1 iddi xKBAx −=+  (13)
In the case of pole placement, the feedback matrix K 
can be determined by the Ackermann’s formula, i.e. 
),(1 dclosedC
T
nPP AMeK ϕ⋅⋅=
−  (14) 
where en is the nth unit vector and φclosed(A) is the 
characteristic polynomial of the closed loop evaluated at 
the matrix Ad. The poles of the closed loop are determined 
by accelerating the poles of the linear continuous model 
and then using Z-transform method (pole–zero mapping): 
,dsTez =  (15) 
where z is the discrete time pole, s is the continuous time 
pole. 
LQ control method aims to minimize the tumor volume 
(x1) using the least possible control signal. The discrete 
time cost function which has to be minimized with the 
constraint (8) is the following: 
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where Q and R are positive definite weighting matrices. 
We chose to minimize the square of the output  
(x12 = y2), thus the Q weighting matrix is: 
.CCQ T=  (17) 
The feedback matrix K for the discrete time LQ 
problem can be calculated by the formula: 
( ) ,1 dTddTdLQ PABPBBRK −+=  (18) 
where P is the solution of the Discrete Control Algebraic 
Ricatti Equation (DARE): 
( )( ) ( ) QPABPBBRPBAPAAP dTddTddTddTd ++−= −1 (19)
C. Setpoint control  
The solution of the state equation in steady state is 
characterized by the equivalence of the previous and 
actual states: 
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Taking into account a constant reference signal, two 
matrices (Nx and Nu) are needed to extend the control 
structure for setpoint control. For zero steady state error 
on the output, the following equations need to be satisfied: 
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Considering on the one hand (21), (22) and (23) 
equations, one can express: 
,mx ICN =  (25)
where dim y = dim r = dim u = m. On the other hand, 
substituting (22) and (24) into (20) leads to the: 
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( ) .0nxmudxd NBNIA =+−  (26)
 
 
Figure 1. Block diagram of the discrete time control containing state feedback, setpoint control, actual state observer and load estimation. 
 
    Finally, equation (25) and (26) can be written in matrix 
equation form that expresses the vector which contains the 
required Nx and Nu matrices:  
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D. Actual state observer  
In discrete time, an actual state observer can be used to 
estimate the non-measurable state variables. 
Let us consider that the matrix MoAd is full rank, i.e. the 
discrete time system is observable with an actual observer. 
In this case we can choose an actual state observer which 
is described by the difference equation: 
.ˆˆ 11 −− ++= iiii HuGyxFx  (28)
Let ix~
 
be the error of estimation: 
,ˆ~ iii xxx −=  (29)
then 
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In order to assure 0~ →ix , we choose the following 
parameters for the actual state observer: 
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Finally, gain G can be calculated using the 
Ackermann’s formula by substituting Ad:=AdT and 
Bd:=AdTCT into (14) and using the prescribed poles 
of the observer to defined the characteristic 
polynomial in (14).  
E. Load estimation 
We assume that the disturbance is reduced to the input 
of the system (load change) and has a constant value. 
Consequently the differential equation of the 
disturbance is: 
.1 ii dd =+ (34)
Extending the system with the state variable of the 
disturbance (xd) and using the notation ( )TTdT xxx ,~ = , the 
state equation becomes: 
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The state feedback and the setpoint control is designed 
for the original system; however, the actual state observer 
has to calculate not only the estimation of the state 
variables ( xˆ ), but the estimation of the disturbance ( dxˆ ) 
as well. Therefore, actual state observer was designed for 
the extended system [17] whose difference equation is: 
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Fig. 1 depicts the whole closed-loop control system 
containing the controller and the nonlinear system. We 
placed saturation between the tumor model and the 
controller. The control input has a lower limit in 
order to exclude negative inputs, since they have no 
physiological meaning; and an upper limit because 
too high input could be dangerous in biological 
systems. 
IV. SIMULATION RESULTS 
Simulations were executed in Simulink 7.9.0. 
Simulation periods were 150 days in all cases and 
endostatin was used as angiogenic inhibitor. Initial value 
of tumor volume and endothelial volume was the steady 
state volume without control input (1.734ˇ104 mm3). 
Acceleration of the actual state observer was ao = 5. 
Control strategies were evaluated based on three 
criteria: (i) the total concentration of the administered 
inhibitor during the treatment (mg/kg), (ii) the steady state 
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inhibitor concentration at the end of the treatment (mg/kg), 
(iii) the steady state tumor volume at the end of the 
treatment (mm3). 
We found that operating point (x10) has a determinative 
effect on the control since the appropriate operating point 
can be chosen only from a narrow range. 
 
Figure 2. Effect of operating point on the evaluation criteria (LQ control, 
saturation: 15 mg/kg; R weighting matrix: 10; reference signal: 5 mm3; 
disturbance: 10%).  
 
If x10 < 100 mm3 or x10 > 250 mm3, the control is not 
effective. For x10 < 100 mm3, the control input before the 
saturation (ui according to Fig. 1) is unusable because its 
amplitude is high and it oscillates with high frequency; for 
x10 > 250 mm3, the 150 days simulation period is not 
enough to reach the steady state. If 100 mm3 < x10 < 250 
mm3, the control strategy is effective and the smallest 
amount of inhibitor is needed in the case of x10 = 100 mm3 
operating point (Fig. 2). 
If the gain of state feedback is calculated based on LQ 
control method, the most important parameter to be 
chosen is the R weighting matrix. Theoretically large R 
attempts to minimize the input, while small R allows high 
inputs; however, we found that larger R values resulted in 
larger total inhibitor concentration (Fig. 3). This behavior 
can be explained by the effect of saturation. Similarly to 
the operating point, R also has a range in which case the 
control strategy is effective (1 < R < 100).  
 
 
Figure 3. Effect of R weighting matrix on the evaluation criteria (LQ 
control, operating point: 100 mm3; saturation: 15 mg/kg; reference 
signal: 5 mm3; disturbance: 10%).  
 
Figure 4. Effect of saturation on the evaluation criteria (LQ control, 
operating point: 100 mm3; R weighting matrix: 10; reference signal: 5 
mm3; disturbance: 10%).  
 
The effect of saturation was found to be very similar to 
the continuous time state feedback [4]. Increasing the 
saturation limit, the total concentration of the administered 
inhibitor also increases, whilst the steady state inhibitor 
concentration slightly decreases and the steady state tumor 
volume remains the same value (Fig. 4). It means that 
lower saturation value is not only appropriate due to 
physiological aspects (less side effects) and economic 
considerations (better cost-effectiveness), but also because 
of engineering point of view. 
In real-life applicability, a key question is the 
prescribed value of reference signal. Evidently, small 
steady state tumor volume has smaller cytotoxic and other 
harmful physiological effect than larger ones; however, 
the problem is more complicated. In cancer treatment, we 
have to take into account cost-effectiveness aspect as well 
which can be accomplished in the following way.  
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Figure 5. Effect of reference signal on the evaluation criteria (LQ control, 
operating point: 100 mm3; saturation: 15 mg/kg; R weighting matrix: 10; 
disturbance: 10%).  
 
Figure 6. Effect of disturbance on the evaluation criteria (LQ control, 
operating point: 100 mm3; saturation: 15 mg/kg; R weighting matrix: 10; 
reference signal: 5 mm3).  
 
 
 
    One has to define oncologically homogenous groups 
which contain a set of cases (e.g. a set of steady state 
tumor volumes) which have nearly the same physiological 
effect to the host organism. Within a certain homogenous 
group, the most cost-effective treatment should be chosen. 
If we can count the 2 mm3 < r < 10 mm3 reference signal 
range as an oncologically homogenous group, the 
selection criterion should be the r which results in the 
smallest total inhibitor concentration, viz. r = 10 mm3 
(Fig. 5). 
The effect of disturbance (d) is also not negligible. A 
possible type of disturbance which is reduced to the input 
of the system can be the error caused by the non-precise 
tumor volume measurement [13]. Fig. 6 shows the effect 
of the disturbance when d is [-10%,+10%] of the 
saturation. One can see that the corresponding total 
inhibitor concentration values vary in a large range (1952 
mg/kg and 1555 mg/kg for -10% and +10%, respectively). 
In addition, the steady state inhibitor concentration also 
varies in a relatively wide range (10.3 mg/kg and 7.5 
mg/kg for -10% and +10%, respectively). 
Finally, if the gain of state feedback is calculated based 
on pole placement, the acceleration (a) of the poles has to 
be set as a parameter. If a < 2, the 150 days simulation 
period is not enough to reach the steady state. Otherwise, 
if a > 5, the system is over-accelerated. Within this range, 
the higher the acceleration, the lower the total inhibitor 
concentration becomes (Fig. 7).  
Fig. 8 shows the reference, input and output signals of 
the tumor growth model in the case of LQ control. One 
can see that the parameters have significant effect on the 
input signal. If the input has large over- and undershoot, it 
will cause larger total inhibitor concentration on the one 
hand, and on the other hand it may result in side-effects 
for the patient.  
 
 
 
Figure 7. Effect of acceleration on the evaluation criteria (pole 
placement, operating point: 100 mm3; saturation: 15 mg/kg; reference 
signal: 5 mm3; disturbance: 10%).  
 
V. CONCLUSION 
We designed state feedback control, augmented with 
setpoint control to follow nonzero reference signal. State 
feedback was realized using both pole placement and LQ 
control method. The control structure is also augmented 
with an actual state observer and load estimation. We 
examined the effect of several parameters on the control 
such as operating point, R weighting matrix, saturation, 
reference signal, disturbance and acceleration. We found 
that a current set of parameters can be chosen in order to 
reduce total inhibitor concentration and avoid side-effect 
as much as possible. 
Further work will focus on the investigation of LPV-
based modeling [18]. 
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Figure 8. Reference, input and output signals of the tumor growth model in the case of LQ control. 
a) Parameters: operating point: 10 mm3; saturation: 13 mg/kg; R: 1; reference signal: 10 mm3; disturbance: 10%.  
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Total inhibitor concentration: 1506 mg/kg, steady state inhibitor concentration: 7.5 mg/kg, steady state tumor volume: 10 mm3. 
b) Parameters: operating point: 10 mm3; saturation: 13 mg/kg; R: 1; reference signal: 5 mm3; disturbance: 10%.  
Total inhibitor concentration: 1550 mg/kg, steady state inhibitor concentration: 7.5 mg/kg, steady state tumor volume: 5 mm3. 
c) Parameters: operating point: 100 mm3; saturation: 15 mg/kg; R: 10; reference signal: 5 mm3; disturbance: 10%.  
Total inhibitor concentration: 1580 mg/kg, steady state inhibitor concentration: 7.3 mg/kg, steady state tumor volume: 5 mm3. 
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